Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 248
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/11/2007
 
First Published:
10/1/1998
1.
Phase IV Study of Allogeneic Marrow Transplants Depleted of T-cells by Differential Agglutination with Soybean Lectin Followed by Rosetting with Sheep Red Blood Cells in Patients Undergoing Allogeneic Bone Marrow Transplantation with an Unrelated Matched Donor or a Related or Unrelated 1 Antigen Mismatched Donor (Summary Last Modified 12/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Closed
50 and under
Other
MSGCC-9720
NCI-V98-1428
Last Modified:
6/1/2001
 
First Published:
9/1/1998
2.
Phase IV Study of Allogeneic Bone Marrow Transplantation Depleted of T-Cells by CD34 Selection in Patients Undergoing Transplantation with a Matched or Mismatched Antigen Donor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Closed
50 and under
Other
MSGCC-9739
NCI-V98-1433, NCT00003398
Last Modified:
7/11/2007
 
First Published:
9/1/1998
3.
Phase IV Study of Allogenic Marrow Transplants Depleted of T-Cells by Differential Agglutination With Soybean Lectin Followed By Rosetting With Sheep Red Blood Cells for Patients Undergoing Allogenic Bone Marrow Transplantation With a Matched-Related Donor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care, Treatment
Closed
Any age
Other
MSGCC-9721
NCI-V98-1438
Last Modified:
3/1/1997
4.
Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
no greater than 60
NCI
NU-93B1
NCI-T93-0058D, T93-0058
Last Modified:
11/1/1994
5.
Phase III Randomized Study of a Single vs Multiple vs No Intravesical Instillation of TSPA Following TURB for Previously Untreated Ta/T1 Transitional Cell Carcinoma of the Bladder (Summary Last Modified 11/94)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
any age
MRC-BS01
EU-94005
Last Modified:
5/8/2007
 
First Published:
6/1/1996
6.
Phase III Randomized Study of Doxorubicin Induction Followed by Either Conventional Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or High Dose Cyclophosphamide and Thiotepa with Peripheral Blood Stem Cell Rescue in Women With Stage II or IIIA Breast Cancer (Summary Last Modified 05/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
over 18
SCTN-BR9405
EU-95048, NCT00002755
Last Modified:
5/8/2007
 
First Published:
6/1/1996
7.
NCI HIGH-PRIORITY CLINICAL TRIAL--Phase III Randomized Study of Intensive Sequential Doxorubicin, Paclitaxel, and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed By STAMP I or STAMP V Combination Chemotherapy With Autologous Stem Cell Rescue in Women With Primary Breast Cancer and At Least 4 Involved Axillary Lymph Nodes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
Adult
NCI
SWOG-S9623
CLB-9640, E-S9623, NCT00002772, S9623
8.
Phase III Pilot Study of Alternating Courses of MOPP and ABDV plus Radiotherapy with or without Levamisole for Advanced Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
no age specified
MSKCC-75104
Last Modified:
5/8/2007
9.
Phase III Randomized Comparison of High Dose Chemotherapy Plus Filgrastim to Filgrastim for Mobilization of Peripheral Blood Stem Cells for Autologous Transplantation for Patients With Responsive Metastatic Breast Cancer or High Risk Stage II and III Patients (Summary Last Modified 06/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 65
NCI
MDA-DM-95047
NCI-G96-1014, NCT00002836
Last Modified:
11/30/2007
 
First Published:
11/1/1996
10.
Phase III Randomized Study of Intensification with Cyclophosphamide/Thiotepa (CHUT) with Autologous PBSC Support vs No Intensification in Women With Locally Recurrent or Metastatic Breast Cancer Responsive to Induction with Epirubicin/Fluorouracil/Cyclophosphamide (FEC 100)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
under 60
FRE-FNCLCC-PEGASE03
EU-96032, NCT00002870
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute